Hope for patients with brain and spinal cord injuries - uses an already-licensed medicine
https://medicalxpress.com/news/2020-05-cell-pores-discovery-millions-brain.html
'Cell pores' discovery gives hope to millions of brain and spinal cord injury patients
by Aston University
May 14, 2020
Scientists have discovered a new treatment to dramatically reduce swelling after brain and spinal cord injuries, offering hope to 75 million victims worldwide each year.
The breakthrough in treating such injuries—referred to as central nervous system (CNS) edema—is thought to be hugely significant because current options are limited to putting patients in an induced coma or performing risky surgery.
…
The researchers used an already-licensed anti-psychotic medicine—trifluoperazine (TFP) - to alter the behaviour of tiny water channel 'pores' in cells known as aquaporins.
Testing the treatment on injured rats, they found those animals given a single dose of the drug at the trauma site recovered full movement and sensitivity in as little as two weeks, compared to an untreated group that continued to show motor and sensory impairment beyond six weeks after the injury.
The treatment works by counteracting the cells' normal reaction to a loss of oxygen in the CNS—the brain and spinal cord—caused by trauma. Under such conditions, cells quickly become 'saltier' because of a build-up of ions, causing a rush of water through the aquaporins which makes the cells swell and exerts pressure on the skull and spine. This build-up of pressure damages fragile brain and spinal cord tissues, disrupting the flow of electrical signals from the brain to the body and vice versa.
But the scientists discovered that TFP can stop this from happening. Focusing their efforts on important star-shaped brain and spinal cord cells called astrocytes, they found TFP prevents a protein called calmodulin from binding with the aquaporins. Normally, this binding effect sends the aquaporins shooting to the surface of the cell, letting in more water. By halting this action, the permeability of the cells is reduced.
Traditionally, TFP has been used to treat patients with schizophrenia and other mental health conditions. Its long-term use is associated with adverse side effects, but the researchers said their experiments suggested that just a single dose could have a significant long-lasting impact for CNS edema patients.
[Moar at website]
Journal article: Cell (2020).
DOI: 10.1016/j.cell.2020.03.037
https://www.cell.com/cell/pdf/S0092-8674(20)30330-5.pdf